Chimeric antigen receptor T‐cell therapy in patients with neurologic comorbidities-Reference-Cited by-同舟云学术

Chimeric antigen receptor T‐cell therapy in patients with neurologic comorbidities

Published:2020-02-04 Issue:4 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Rubinstein Jeremy D.¹²^ORCID,Nelson Adam S.¹³,Krupski Christa¹³,O'Brien William⁴⁵,Taylor J. Michael¹⁶,Badgett Tom C.⁷,Huang Michael⁸,Davies Stella M.¹³,Phillips Christine L.¹²

Affiliation:

1. Department of PediatricsUniversity of Cincinnati College of Medicine Cincinnati Ohio

2. Division of Oncology, Cancer and Blood Disease InstituteCincinnati Children's Hospital Medical Center Cincinnati Ohio

3. Division of Bone Marrow Transplantation and Immune DeficiencyCancer and Blood Disease InstituteCincinnati Children's Hospital Medical Center Cincinnati Ohio

4. Department of RadiologyUniversity of Cincinnati College of Medicine Cincinnati Ohio

5. Department of Radiology and Medical ImagingCincinnati Children's Hospital Medical Center Cincinnati Ohio

6. Division of NeurologyCincinnati Children's Hospital Medical Center Cincinnati Ohio

7. Department of PediatricsUniversity of Kentucky College of MedicineLexington Kentucky

8. Pediatric Cancer and Blood DisordersUniversity of Louisville School of MedicineLouisville Kentucky

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28199

Reference18 articles.

1. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

2. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

3. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

4. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

5. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review;Frontiers in Oncology;2024-01-23

2. Severe persistent neurotoxicity associated with CAR T therapy in children;British Journal of Haematology;2023-08

3. Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity;Journal of Immunotherapy;2022-08-29

4. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment;Blood Advances;2022-05-17

5. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report;Blood Advances;2022-01-21